IRCT201605159014N98已完成2 期
Effect of Teriparatide, Alendronate, and Zoledronic Acid on treatment of secondary osteoporosis: a randomized clinical trial
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •(a) secondary osteoporosis; (b) T-score less than -2.5 in the lumbar spine or femoral neck.
- •Exclusion criteria: (a) primary osteoporosis; (b) using prednisolone more than 3 months; (c) rheumatologic disease; (d) malignancy; (e) hypothyroidism; (f) renal failure; (g) history of surgery of parathyroid gland.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Effect of Teriparatide, Alendronate, Zoledronic Acid, and combined effect of Teriparatide and Alendronate treatment of primary osteoporosisOsteoporosis.Idiopathic osteoporosisIRCT201605169014N99Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences120
已完成
不适用
Preventive effects with teriparatide or alendronate on the progression of vertebral collapseOsteoporosisJPRN-UMIN000013014Kitakyushu Osteoporosis Trial Unit200
已完成
不适用
Comparison of alendronate and teriparatide for the bone mineral density around implant after total hip arthroplastycases after primary total hip arthroplastyJPRN-UMIN000016158Yokohama City University60
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip FractureEUCTR2008-002693-35-GBEli Lilly and Company Ltd171
进行中（未招募）
1 期
Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture - GHDKPostmenopausal Women and Men with Low Bone Mass and a Recent Pertrochanteric FractureMedDRA version: 9.1Level: LLTClassification code 10031282Term: OsteoporosisEUCTR2008-002693-35-NOEli Lilly and Company Ltd171